Clinical Trial Update: Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining indirect neuroprotective effects of Tecfidera (dimethyl fumarate) in relapsing-remitting and progressive multiple sclero…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Multiple Sclerosis Center of Northeastern New York | Conditions: Multiple Sclerosis | Phase 4 | Status: UNKNOWN